Cannabinoids for Medical Use: A Systematic Review and Meta-analysis (JAMA)

Technical Workshops

AHPA regularly presents in-person technical workshops to train the herbal products industry on the latest tools and methods that help ensure high-quality products and compliance with federal and state regulations.

Upcoming Events

Cannabinoids for Medical Use: A Systematic Review and Meta-analysis (JAMA)

Author: Lawanda (Admin)/Friday, October 30, 2015/Categories: Science Alert

Journal of the American Medical Association

DOI:10.1001/jama.2015.6358 

June 2015

 

Cannabinoids for Medical Use:  A Systematic Review and Meta-analysis

 

Abstract

 

Importance: Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear.

 

Objective: To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids.

 

Data Sources: Twenty-eight databases from inception to April 2015.

Study Selection  Randomized clinical trials of cannabinoids for the following indications: nausea and vomiting due to chemotherapy, appetite stimulation in HIV/AIDS, chronic pain, spasticity due to multiple sclerosis or paraplegia, depression, anxiety disorder, sleep disorder, psychosis, glaucoma, or Tourette syndrome.

 

Data Extraction and Synthesis: Study quality was assessed using the Cochrane risk of bias tool. All review stages were conducted independently by 2 reviewers. Where possible, data were pooled using random-effects meta-analysis.

 

Main Outcomes and Measures: Patient-relevant/disease-specific outcomes, activities of daily living, quality of life, global impression of change, and AEs.

Results  A total of 79 trials (6462 participants) were included; 4 were judged at low risk of bias. Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials. Compared with placebo, cannabinoids were associated with a greater average number of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95% CI, 1.55-9.42]; 3 trials), reduction in pain (37% vs 31%; OR, 1.41 [95% CI, 0.99-2.00]; 8 trials), a greater average reduction in numerical rating scale pain assessment (on a 0-10-point scale; weighted mean difference [WMD], −0.46 [95% CI, −0.80 to −0.11]; 6 trials), and average reduction in the Ashworth spasticity scale (WMD, −0.12 [95% CI, −0.24 to 0.01]; 5 trials). There was an increased risk of short-term AEs with cannabinoids, including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination.

 

Conclusions and Relevance: There was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. There was low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term AEs.

 

[READ MORE...]

  

The links above are provided as a convenience, however, web pages are often updated by their host sites and this link may not remain active. AHPA gathers information from many organizations. Some sites require you to register in order to read articles. 
Print

Number of views (3518)/Comments (0)

Tags:

2017 Annual Fund Sponsors

           

AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.